Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: Results of a pilot study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F17%3A43912286" target="_blank" >RIV/00216208:11120/17:43912286 - isvavai.cz</a>

Alternative codes found

RIV/00064173:_____/17:N0000064

Result on the web

<a href="http://dx.doi.org/10.1111/1346-8138.13661" target="_blank" >http://dx.doi.org/10.1111/1346-8138.13661</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/1346-8138.13661" target="_blank" >10.1111/1346-8138.13661</a>

Result language

angličtina

Original language name

Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: Results of a pilot study

Original language description

Psoriasis is a chronic systemic immune-mediated inflammatory dermatosis associated with several comorbidities. Psoriasis patients are at increased risk of developing cardiovascular diseases (CVD), namely, coronary heart disease, stroke or peripheral vascular disease, and psoriasis seems to be an independent cardiovascular risk factor. Antipsoriatic systemic therapy, especially anti-tumor necrosis factor (TNF)-α, seems to exert a beneficial effect on these comorbidities. The purpose of this study was: (i) to measure the level of cardiovascular serum markers in psoriasis patients in comparison with healthy volunteers; and (ii) to compare the serum level of the same markers in patients before and 3 months after adalimumab therapy. We investigated six biomarkers connected to CVD: C-reactive protein (measured high sensitively, hsCRP), oxidized low-density lipoproteins (oxLDL), oxLDL/β-glycoprotein I complex (oxLDL/β2GPI), vascular endothelial adhesion molecule 1 (VCAM-1), E-selectin and interleukin (IL)-22. These biomarkers were measured in 21 patients with moderate/severe psoriasis before and after treatment with adalimumab and in healthy volunteers. hsCRP (P &lt; 0.05), oxLDL-β2GPI complex (P &lt; 0.05), E-selectin (P &lt; 0.001) and IL-22 (P &lt; 0.001) were significantly increased in comparison with healthy controls, whereas oxLDL and VCAM-1 were also higher in psoriasis patients but the difference did not reach statistical significance. A decrease of E-selectin (P &lt; 0.001) and IL-22 (P &lt; 0.001) was observed after 3 months of adalimumab therapy. Inhibition of TNF-α seems to not only improve psoriasis but also decreases serum cardiovascular biomarkers. E-selectin and IL-22 could serve for monitoring of the efficacy of antipsoriatic systemic therapy on cardiovascular risk.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30216 - Dermatology and venereal diseases

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

The Journal of Dermatology

ISSN

0385-2407

e-ISSN

—

Volume of the periodical

44

Issue of the periodical within the volume

4

Country of publishing house

GB - UNITED KINGDOM

Number of pages

7

Pages from-to

363-369

UT code for WoS article

000398690600017

EID of the result in the Scopus database

2-s2.0-84997787494